

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. - 9. (Canceled)

10. (Currently amended) A method for producing an antigen specific cytotoxic T cell response, comprising: administering, to a patient in need thereof, a composition consisting essentially of an effective amount of human dendritic cells, exposed *in vitro* to a soluble, exogenous tissue specific antigen and bacillus Calmette Guerin (BCG) or BCG with lipopolysaccharide (LPS) to induce antigen processing and to promote Major Histocompatibility Complex- (MHC-) class I presentation of the antigen, such that after administration the human dendritic cells presenting the antigen in the context of MHC-class I elicit the antigen specific cytotoxic T cell immune response.

11. (Canceled)

12. (Original) The method according to claim 10, in which the antigen is a lysate of cancer tumor cells isolated from a patient, a membrane preparation of tumor cells isolated from a patient, a purified tumor specific antigen, a purified tumor associated antigen, a purified tissue associated antigen, a purified tissue specific antigen, or an antigenic fragment thereof.

13. (Original) The method according to claim 12, in which the antigen is a prostate tumor associated antigen.

14. (Previously presented) The method according to claim 12, in which the prostate tumor associated antigen is a lysate of prostate tumor cells of a prostate cancer patient, a membrane preparation of prostate tumor cells of a prostate cancer patient, purified prostate specific membrane antigen (PSMA), a peptide having the amino acid sequence Leu Leu His Glu

Thr Asp Ser Ala Val (SEQ ID NO. 1), a peptide having the amino acid sequence Ala Leu Phe Asp Ile Glu Ser Lys Val (SEQ ID NO. 2), a peptide having the amino acid sequence Xaa Leu (or Met) Xaa Xaa Xaa Xaa Xaa Val (or Leu) where Xaa represents any amino acid, purified prostate specific antigen (PSA), purified prostate acid phosphatase (PAP), six transmembrane epithelial antigen of the prostate (STEAP), prostate carcinoma tumor antigen (PCTA-1), prostate stem cell antigen (PSCA), or purified prostate mucus antigen recognized by monoclonal antibody PD41.

15. (Canceled)

16. (Previously presented) The method according to claim 10, in which the human dendritic cells are obtained from skin, spleen, thymus, bone marrow, lymph nodes, chord blood, or peripheral blood of the patient.

17. (Previously presented) The method according to claim 10, in which the human dendritic cells are obtained from peripheral blood.

18. (Previously presented) The method according to claim 10, in which the dendritic cells are obtained from a healthy individual HLA-matched to the patient.

19. (Original) The method according to claim 10, in which the dendritic cells are extended life span dendritic cells.

20. (Previously presented) The method according to claim 10, in which the human dendritic cells are cryopreserved and then thawed prior to administration to the patient.

21. (Original) The method according to claim 10, in which the patient is suffering from metastatic prostate cancer.

22. - 35. (Canceled).

36. (Previously presented) The method according to claim 10, wherein the antigen and the BCG or BCG and LPS are combined with the dendritic cells simultaneously.

37. (Previously presented) The method according to claim 36, in which the antigen is a lysate of cancer tumor cells isolated from a patient, a membrane preparation of tumor cells isolated from a patient, a purified tumor specific antigen, a purified tumor associated antigen, a purified tissue associated antigen, a purified tissue specific antigen, or an antigenic fragment thereof.

38. (Previously presented) The method according to claim 37, in which the antigen is a prostate tumor associated antigen.

39. (Previously presented) The method according to claim 38, in which the prostate tumor associated antigen is a lysate of prostate tumor cells of a prostate cancer patient, a membrane preparation of prostate tumor cells of a prostate cancer patient, purified prostate specific membrane antigen (PSMA), a peptide having the amino acid sequence Leu Leu His Glu Thr Asp SEr Ala Val (SEQ ID NO: 1), a peptide having the amino acid sequence Ala Leu Phe Asp Ile Glu Ser Lys Val (SEQ ID NO: 2), a peptide having the amino acid sequence Xaa Leu (or Met) Xaa Xaa Xaa Xaa Val (or Leu) where X represents any amino acid, purified prostate specific antigen (PSA), purified prostate acid phosphatase (PAP), six transmembrane epithelial antigen of the prostate (STEAP), prostate carcinoma tumor antigen (PCTA-1), prostate stem cell antigen (PSCA), or purified prostate mucus antigen recognized by monoclonal antibody PD41.

40. - 43. (Canceled) The method according to claim 10, wherein the antigen is contacted with the dendritic cells subsequent to contact of the dendritic cells with BCG or BCG and LPS.